Drug
Klu156
Klu156: highest development phase Phase 3, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| KLU156 NCT05842954 | Phase 3 | Uncomplicated Plasmodium Falciparum Malaria |
Latest
No recent events.
Follow Klu156 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.